Stage IA-IB adenocarcinoma of the lung
Conditions
Interventions
Control group:Placebo
Sponsors
Department of Oncology of Shanghai Traditional Chinese Medicine Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Patients conforming to lung adenocarcinoma, with stage Ia and Ib clinical stages and without adjuvant therapy after radical resection, within half a year after operation; (2) Patients aged between 18 and 80 years; (3) Blood routine and biochemical indexes are basically normal, and there is no serious virus or bacterial infection;Patients without organ failure or severe heart disease (hemobilirubin3.5x10^9/L and lower than 12x10^9/L, platelet count>80x10^9/L, hematocrit >0.20); (4) No other serious complications; (5) I agree to participate in the study and sign the informed consent with good compliance; (6) Non-pregnant or lactating patients; (7) No allergic reaction to the compatible ingredients in the prescription.
Exclusion criteria
Exclusion criteria: (1) Patients with cancer recurrence or metastasis; (2) Patients receiving other drug intervention treatment (including other traditional Chinese medicine decoction pieces, chemotherapy, targeted drugs); (3) Having a mental illness; Lack of autonomous behavior ability; (4) Women who are pregnant or preparing for pregnancy or breastfeeding. (5) Patients with heart, lung, brain, liver, kidney, hematopoietic system and other serious diseases or mental diseases; (6) Allergic constitution or known allergy to the composition of this drug; (7) Patients who are participating in other clinical trials or who have participated in other clinical trials within 3 months; (8) Alcoholics and/or psychoactive substances, substance abusers and dependents; (9) According to the judgment of the researchers, there are other lesions or conditions that reduce the possibility of enrollment or complicate enrollment, such as frequent changes in the working environment and unstable living environment, which may easily lead to loss of follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| recurrence rate;OS;PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| NK cells (CD3-CD56dimCD16+);NSE;MDSC(CD11b+ Gr-1+);SCC;Treg (CD4+CD25+Foxp3+);T cell subsets (CD3+CD4+CD8+);B cells (CD19+);CEA;CY-211; | — |
Countries
China
Contacts
Public ContactLi Yan
Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chin
Outcome results
None listed